BioScrip (NASDAQ:BIOS) Sees Strong Trading Volume

Share on StockTwits

BioScrip Inc (NASDAQ:BIOS) saw unusually-high trading volume on Monday . Approximately 4,108,505 shares were traded during mid-day trading, an increase of 249% from the previous session’s volume of 1,175,782 shares.The stock last traded at $2.76 and had previously closed at $2.60.

BIOS has been the topic of a number of research analyst reports. TheStreet cut shares of Red Lion Hotels from a “c” rating to a “d+” rating in a research note on Wednesday, April 3rd. Barrington Research reissued a “buy” rating and issued a $4.00 price target on shares of BioScrip in a research report on Friday, May 3rd. BidaskClub raised shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Thursday, May 9th. Stephens began coverage on shares of Arcosa in a research report on Monday, March 18th. They issued an “equal weight” rating on the stock. Finally, Zacks Investment Research raised shares of Hanmi Financial from a “sell” rating to a “hold” rating in a research report on Thursday, June 20th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. BioScrip currently has a consensus rating of “Buy” and a consensus target price of $4.60.

The firm’s 50-day moving average is $2.32. The firm has a market capitalization of $334.77 million, a P/E ratio of -5.63 and a beta of 0.68.

BioScrip (NASDAQ:BIOS) last posted its earnings results on Thursday, May 2nd. The company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.01. The firm had revenue of $178.96 million for the quarter, compared to the consensus estimate of $179.23 million. The business’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted ($0.12) EPS. On average, equities analysts expect that BioScrip Inc will post -0.25 EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its holdings in BioScrip by 43.8% during the fourth quarter. Rhumbline Advisers now owns 182,883 shares of the company’s stock valued at $653,000 after purchasing an additional 55,674 shares in the last quarter. California Public Employees Retirement System increased its holdings in BioScrip by 28.2% in the 4th quarter. California Public Employees Retirement System now owns 347,831 shares of the company’s stock worth $1,242,000 after buying an additional 76,531 shares during the period. BlackRock Inc. increased its holdings in BioScrip by 28.8% in the 4th quarter. BlackRock Inc. now owns 9,807,734 shares of the company’s stock worth $35,013,000 after buying an additional 2,191,490 shares during the period. Dimensional Fund Advisors LP increased its holdings in BioScrip by 7.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,617,021 shares of the company’s stock worth $9,342,000 after buying an additional 180,389 shares during the period. Finally, Geode Capital Management LLC increased its holdings in BioScrip by 12.1% in the 4th quarter. Geode Capital Management LLC now owns 1,472,760 shares of the company’s stock worth $5,257,000 after buying an additional 158,927 shares during the period. 78.60% of the stock is currently owned by institutional investors and hedge funds.

BioScrip Company Profile (NASDAQ:BIOS)

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Recommended Story: The primary rules of Elliott Wave theory

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.